Lupin Limited on July 15 announced the divestment of its US commercial women’s health specialty business to Evofem Biosciences, a biopharmaceutical company based in the United States, which focuses exclusively on women’s health, the former said in an exchange filing.
Under the deal, Lupin can get a potential total consideration of up to $84 million based on future contingent milestones, the company said.
Fabrice Egros, president, global corporate development, Lupin said, “We are very pleased to divest our US commercial women’s health specialty business, including SOLOSEC, to Evofem. This divestment is another step in aligning our US specialty business with our strategic plan to build our specialty business in therapeutic areas where we have building blocks of synergy. These include respiratory and neurological diseases.”
Shares of the global pharma major closed 1.69 percent higher at Rs 1,828.05 on NSE.
Lupin’s US commercial women’s health specialty business is primarily focused on commercialising SOLOSEC (secnidazole) 2g oral granules, which is an FDA-approved single-dose antimicrobial agent that provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections, according to the filing.
“The acquisition of this commercial business aligns with and advances our mission to improve access to innovative and differentiated options that impact women’s daily lives. SOLOSEC is a commercially attractive, single-dose oral antibiotic that addresses two pervasive sexual health infections. We can now fully leverage our commercial infrastructure, maximize our strong physician relationships, and re-launch an asset with tremendous growth potential,” said Saundra Pelletier, chief executive officer, Evofem.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
